Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment
äºBeneficial MicrobesInstitute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by F.R. Ponziani in
Current site
Google Scholar
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by F. Scaldaferri in
Current site
Google Scholar
Search for other papers by M. De Siena in
Current site
Google Scholar
Search for other papers by F. Mangiola in
Current site
Google Scholar
Search for other papers by M.V. Matteo in
Current site
Google Scholar
Search for other papers by S. Pecere in
Current site
Google Scholar
Search for other papers by V. Petito in
Current site
Google Scholar
Search for other papers by F. Paroni Sterbini in
Current site
Google Scholar
Search for other papers by L.R. Lopetuso in
Current site
Google Scholar
Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.
Search for other papers by L. Masucci in
Current site
Google Scholar
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by G. Cammarota in
Current site
Google Scholar
Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.
Search for other papers by M. Sanguinetti in
Current site
Google Scholar
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by A. Gasbarrini in
Current site
Google Scholar
Compositional and functional alterations of the gut microbiota are involved in the pathogenesis of several gastrointestinal diseases. Rifaximin is often used to induce disease remission due to its eubiotic effects on the gut microbiota. To investigate the correlation between changes in the gut microbiota composition and symptoms improvement in patients who present a clinical response to rifaximin treatment. Patients with ulcerative colitis (UC), Crohnâs disease (CD), irritable bowel syndrome (IBS) and diverticular disease (DD) undergoing rifaximin treatment for clinical indication were enrolled in the study. Rifaximin was administered at the dose of 1,200 mg/day for 10 days. Faecal samples were collected at baseline and at the end of treatment; clinical improvement was assessed by Mayo score for UC, CD Activity Index (CDAI) for CD, IBS severity scoring system (IBS-SSS) for IBS and global symptomatic score (GSS) for DD. Twenty-five patients were included in the analysis and a clinical improvement was recorded for 10/25 (40%) of them. Microbial alpha diversity showed a slight increase in clinical responders (P=0.271), while it decreased in patients who did not improved (P=0.05). A significant post-treatment increase in Faecalibacterium abundance was observed in patients with a positive response (log2FC 1.959, P=0.042). Roseburia abundance decreased in both groups, whereas Ruminococcus decreased only in patients who clinically improved. Clinical improvement consequent to rifaximin treatment is associated with an increase in Faecalibacterium abundance. Achieving a positive shift in the gut microbiota composition seems a key event to obtain a clinical benefit from treatment.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Bajaj, J.S., Barbara, G., DuPont, H.L., Mearin, F., Gasbarrini, A. and Tack, J., 2018. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Digestive and Liver Disease 50: 741-749. https://doi.org/10.1016/j.dld.2018.04.020
-
Bajaj, J.S., Heuman, D.M., Sanyal, A.J., Hylemon, P.B., Sterling, R.K., Stravitz, R.T., Fuchs, M., Ridlon, J.M., Daita, K., Monteith, P., Noble, N.A., White, M.B., Fisher, A., Sikaroodi, M., Rangwala, H. and Gillevet, P.M., 2013. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE 8: e60042. https://doi.org/10.1371/journal.pone.0060042
-
Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M. and Matteuzzi, D., 2002. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. Journal of Chemotherapy 14: 290-295. https://doi.org/10.1179/joc.2002.14.3.290
-
Canfora, E.E., Meex, R.C.R., Venema, K. and Blaak, E.E., 2019. Gut microbial metabolites in obesity, NAFLD and T2DM. Nature Reviews: Endocrinology 15: 261-273. https://doi.org/10.1038/s41574-019-0156-z
-
Ferreira-Halder, C.V., Faria, A.V.S. and Andrade, S.S., 2017. Action and function of Faecalibacterium prausnitzii in health and disease. Best Practice and Research: Clinical Gastroenterology 31: 643-648. https://doi.org/10.1016/j.bpg.2017.09.011
-
Franzosa, E.A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H.J., Reinker, S., Vatanen, T., Hall, A.B., Mallick, H., McIver, L.J., Sauk, J.S., Wilson, R.G., Stevens, B.W., Scott, J.M., Pierce, K., Deik, A.A., Bullock, K., Imhann, F., Porter, J.A., Zhernakova, A., Fu, J., Weersma, R.K., Wijmenga, C., Clish, C.B., Vlamakis, H., Huttenhower, C. and Xavier, R.J., 2019. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature Microbiology 4: 293-305. https://doi.org/10.1038/s41564-018-0306-4
-
Gatta, L. and Scarpignato, C., 2017. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology and Therapeutics 45: 604-616. https://doi.org/10.1111/apt.13928
-
Hansen, L.B.S., Roager, H.M., Sondertoft, N.B., Gobel, R.J., Kristensen, M., Valles-Colomer, M., Vieira-Silva, S., Ibrugger, S., Lind, M.V., Maerkedahl, R.B., Bahl, M.I., Madsen, M.L., Havelund, J., Falony, G., Tetens, I., Nielsen, T., Allin, K.H., Frandsen, H.L., Hartmann, B., Holst, J.J., Sparholt, M.H., Holck, J., Blennow, A., Moll, J.M., Meyer, A.S., Hoppe, C., Poulsen, J.H., Carvalho, V., Sagnelli, D., Dalgaard, M.D., Christensen, A.F., Lydolph, M.C., Ross, A.B., Villas-Boas, S., Brix, S., Sicheritz-Ponten, T., Buschard, K., Linneberg, A., Rumessen, J.J., Ekstrom, C.T., Ritz, C., Kristiansen, K., Nielsen, H.B., Vestergaard, H., Faergeman, N.J., Raes, J., Frokiaer, H., Hansen, T., Lauritzen, L., Gupta, R., Licht, T.R. and Pedersen, O., 2018. A low-gluten diet induces changes in the intestinal microbiome of healthy Danish adults. Nature Communications 9: 4630. https://doi.org/10.1038/s41467-018-07019-x
-
Henke, M.T., Kenny, D.J., Cassilly, C.D., Vlamakis, H., Xavier, R.J. and Clardy, J., 2019. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohnâs disease, produces an inflammatory polysaccharide. Proceedings of the National Academy of Sciences of the USA 116: 12672-12677. https://doi.org/10.1073/pnas.1904099116
-
Hold, G.L., Schwiertz, A., Aminov, R.I., Blaut, M. and Flint, H.J., 2003. Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Applied and Environmental Microbiology 69: 4320-4324. https://doi.org/10.1128/aem.69.7.4320-4324.2003
-
Kaji, K., Takaya, H., Saikawa, S., Furukawa, M., Sato, S., Kawaratani, H., Kitade, M., Moriya, K., Namisaki, T., Akahane, T., Mitoro, A. and Yoshiji, H., 2017. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World Journal of Gastroenterology 23: 8355-8366. https://doi.org/10.3748/wjg.v23.i47.8355
-
Larsen, J.M., 2017. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151: 363-374. https://doi.org/10.1111/imm.12760
-
Lopetuso, L.R., Napoli, M., Rizzatti, G. and Gasbarrini, A., 2018. The intriguing role of rifaximin in gut barrier chronic inflammation and in the treatment of Crohnâs disease. Expert Opinions in Investigating Drugs 27: 543-551. https://doi.org/10.1080/13543784.2018.1483333
-
Maccaferri, S., Vitali, B., Klinder, A., Kolida, S., Ndagijimana, M., Laghi, L., Calanni, F., Brigidi, P., Gibson, G.R. and Costabile, A., 2010. Rifaximin modulates the colonic microbiota of patients with Crohnâs disease: an in vitro approach using a continuous culture colonic model system. Journal of Antimicrobial Chemotherapy 65: 2556-2565. https://doi.org/10.1093/jac/dkq345
-
Maharshak, N., Ringel, Y., Katibian, D., Lundqvist, A., Sartor, R.B., Carroll, I.M. and Ringel-Kulka, T., 2018. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Digestive Diseases and Sciences 63: 1890-1899. https://doi.org/10.1007/s10620-018-5086-4
-
Martin, R., Miquel, S., Benevides, L., Bridonneau, C., Robert, V., Hudault, S., Chain, F., Berteau, O., Azevedo, V., Chatel, J.M., Sokol, H., Bermudez-Humaran, L.G., Thomas, M. and Langella, P., 2017. Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Frontiers in Microbiology 8: 1226. https://doi.org/10.3389/fmicb.2017.01226
-
McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R. and Hold, G.L., 2018. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Alimentary Pharmacology and Therapeutics 47: 26-42. https://doi.org/10.1111/apt.14384
-
Nanda Kumar, N.S., Balamurugan, R., Jayakanthan, K., Pulimood, A., Pugazhendhi, S. and Ramakrishna, B.S., 2008. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. Journal of Gastroenterology and Hepatology 23: 1834-1839. https://doi.org/10.1111/j.1440-1746.2008.05723.x
-
Pimentel, M., Morales, W., Chua, K., Barlow, G., Weitsman, S., Kim, G., Amichai, M.M., Pokkunuri, V., Rook, E., Mathur, R. and Marsh, Z., 2011. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Digestive Diseases and Sciences 56: 2067-2072. https://doi.org/10.1007/s10620-011-1728-5
-
Pittayanon, R., Lau, J.T., Yuan, Y., Leontiadis, G.I., Tse, F., Surette, M. and Moayyedi, P., 2019. Gut microbiota in patients with irritable bowel syndrome â a systematic review. Gastroenterology 157: 97-108. https://doi.org/10.1053/j.gastro.2019.03.049
-
Ponziani, F.R., Pecere, S., Lopetuso, L., Scaldaferri, F., Cammarota, G. and Gasbarrini, A., 2016a. Rifaximin for the treatment of irritable bowel syndrome â a drug safety evaluation. Expert Opinion on Drug Safety 15: 983-991. https://doi.org/10.1080/14740338.2016.1186639
-
Ponziani, F.R., Scaldaferri, F., Petito, V., Paroni Sterbini, F., Pecere, S., Lopetuso, L.R., Palladini, A., Gerardi, V., Masucci, L., Pompili, M., Cammarota, G., Sanguinetti, M. and Gasbarrini, A., 2016b. The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin. Digestive Diseases 34: 269-278. https://doi.org/10.1159/000443361
-
Ponziani, F.R., Zocco, M.A., DâAversa, F., Pompili, M. and Gasbarrini, A., 2017. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World Journal of Gastroenterology 23: 4491-4499. https://doi.org/10.3748/wjg.v23.i25.4491
-
Prosberg, M., Bendtsen, F., Vind, I., Petersen, A.M. and Gluud, L.L., 2016. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 51: 1407-1415. https://doi.org/10.1080/00365521.2016.1216587
-
Quevrain, E., Maubert, M.A., Michon, C., Chain, F., Marquant, R., Tailhades, J., Miquel, S., Carlier, L., Bermudez-Humaran, L.G., Pigneur, B., Lequin, O., Kharrat, P., Thomas, G., Rainteau, D., Aubry, C., Breyner, N., Afonso, C., Lavielle, S., Grill, J.P., Chassaing, G., Chatel, J.M., Trugnan, G., Xavier, R., Langella, P., Sokol, H. and Seksik, P., 2016. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohnâs disease. Gut 65: 415-425. https://doi.org/10.1136/gutjnl-2014-307649
-
Scaioli, E., Colecchia, A., Marasco, G., Schiumerini, R. and Festi, D., 2016. Pathophysiology and therapeutic strategies for symptomatic uncomplicated diverticular disease of the colon. Digestive Diseases and Sciences 61: 673-683. https://doi.org/10.1007/s10620-015-3925-0
-
Scarpellini, E., Gabrielli, M., Lauritano, C.E., Lupascu, A., Merra, G., Cammarota, G., Cazzato, I.A., Gasbarrini, G. and Gasbarrini, A., 2007. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics 25: 781-786. https://doi.org/10.1111/j.1365-2036.2007.03259.x
-
Scarpignato, C., Barbara, G., Lanas, A. and Strate, L.L., 2018. Management of colonic diverticular disease in the third millennium: highlights from a symposium held during the United European Gastroenterology Week 2017. Therapeutic Advances in Gastroenterology 11: 1756284818771305. https://doi.org/10.1177/1756284818771305
-
Shafran, I. and Burgunder, P., 2010. Adjunctive antibiotic therapy with rifaximin may help reduce Crohnâs disease activity. Digestive Diseases and Sciences 55: 1079-1084. https://doi.org/10.1007/s10620-009-1111-y
-
Shen, Z., Zhu, C., Quan, Y., Yang, J., Yuan, W., Yang, Z., Wu, S., Luo, W., Tan, B. and Wang, X., 2018. Insights into Roseburia intestinalis which alleviates experimental colitis pathology by inducing anti-inflammatory responses. Journal of Gastroenterology and Hepatology 33: 1751-1760. https://doi.org/10.1111/jgh.14144
-
Simren, M. and Tack, J., 2018. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nature Reviews: Gastroenterology and Hepatology 15: 589-605. https://doi.org/10.1038/s41575-018-0034-5
-
Soldi, S., Vasileiadis, S., Uggeri, F., Campanale, M., Morelli, L., Fogli, M.V., Calanni, F., Grimaldi, M. and Gasbarrini, A., 2015. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clinical and Experimental Gastroenterology 8: 309-325. https://doi.org/10.2147/CEG.S89999
-
Spiller, R. and Major, G., 2016. IBS and IBD â separate entities or on a spectrum? Nature Reviews: Gastroenterology and Hepatology 13: 613-621. https://doi.org/10.1038/nrgastro.2016.141
-
Van de Wiele, T., Van Praet, J.T., Marzorati, M., Drennan, M.B. and Elewaut, D., 2016. How the microbiota shapes rheumatic diseases. Nature Reviews: Rheumatology 12: 398-411. https://doi.org/10.1038/nrrheum.2016.85
-
Xu, D., Gao, J., Gillilland, M., 3rd, Wu, X., Song, I., Kao, J.Y. and Owyang, C., 2014. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146: 484-496 e484. https://doi.org/10.1053/j.gastro.2013.10.026
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 826 | 244 | 13 |
| å ¨ææµè§æ¬¡æ° | 29 | 5 | 0 |
| PDFä¸è½½æ¬¡æ° | 25 | 4 | 0 |
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment
äºBeneficial MicrobesInstitute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by F.R. Ponziani in
Current site
Google Scholar
PubMed
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by F. Scaldaferri in
Current site
Google Scholar
PubMed
Search for other papers by M. De Siena in
Current site
Google Scholar
PubMed
Search for other papers by F. Mangiola in
Current site
Google Scholar
PubMed
Search for other papers by M.V. Matteo in
Current site
Google Scholar
PubMed
Search for other papers by S. Pecere in
Current site
Google Scholar
PubMed
Search for other papers by V. Petito in
Current site
Google Scholar
PubMed
Search for other papers by F. Paroni Sterbini in
Current site
Google Scholar
PubMed
Search for other papers by L.R. Lopetuso in
Current site
Google Scholar
PubMed
Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.
Search for other papers by L. Masucci in
Current site
Google Scholar
PubMed
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by G. Cammarota in
Current site
Google Scholar
PubMed
Institute of Microbiology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.
Search for other papers by M. Sanguinetti in
Current site
Google Scholar
PubMed
Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Search for other papers by A. Gasbarrini in
Current site
Google Scholar
PubMed
Compositional and functional alterations of the gut microbiota are involved in the pathogenesis of several gastrointestinal diseases. Rifaximin is often used to induce disease remission due to its eubiotic effects on the gut microbiota. To investigate the correlation between changes in the gut microbiota composition and symptoms improvement in patients who present a clinical response to rifaximin treatment. Patients with ulcerative colitis (UC), Crohnâs disease (CD), irritable bowel syndrome (IBS) and diverticular disease (DD) undergoing rifaximin treatment for clinical indication were enrolled in the study. Rifaximin was administered at the dose of 1,200 mg/day for 10 days. Faecal samples were collected at baseline and at the end of treatment; clinical improvement was assessed by Mayo score for UC, CD Activity Index (CDAI) for CD, IBS severity scoring system (IBS-SSS) for IBS and global symptomatic score (GSS) for DD. Twenty-five patients were included in the analysis and a clinical improvement was recorded for 10/25 (40%) of them. Microbial alpha diversity showed a slight increase in clinical responders (P=0.271), while it decreased in patients who did not improved (P=0.05). A significant post-treatment increase in Faecalibacterium abundance was observed in patients with a positive response (log2FC 1.959, P=0.042). Roseburia abundance decreased in both groups, whereas Ruminococcus decreased only in patients who clinically improved. Clinical improvement consequent to rifaximin treatment is associated with an increase in Faecalibacterium abundance. Achieving a positive shift in the gut microbiota composition seems a key event to obtain a clinical benefit from treatment.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 826 | 244 | 13 |
| å ¨ææµè§æ¬¡æ° | 29 | 5 | 0 |
| PDFä¸è½½æ¬¡æ° | 25 | 4 | 0 |
